BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on Józwiak et al

Sikiric P, Seiwerth S, Skrtic A, Staresinic M, Strbe S, Boban Blagaic A, Dobric I, et al. · Pharmaceuticals

The originating group answers the tumour and neurodegeneration concerns directly: it reports that BPC 157 does not produce corneal neovascularisation but opposes it, cites anti-tumour effects in vivo and in vitro, and points to counteraction of Parkinson-like and Alzheimer-like disturbances in rodent models. The published exchange is the clearest record of the field's central disagreement.

Population

Formal published comment defending the cytoprotection account against the 2025 Józwiak review

Intervention

n/a

Comparator

n/a

Limitations

A comment rather than new data; every counter-argument is supported by the commenting group's own studies, which is the structure of the disagreement rather than its resolution.